After twenty months of closure of the US borders due to COVID-19, the United States announced at the end of September that it would be reopening on 8 November.
After the long-awaited resumption of events in France, the gradual return to normal is confirmed with the forthcoming opening of the American borders to tourists and business travelers from all over the world.
Chabé is ready to accompany tourists and business travelers from all over the world for all their travel needs during their authorized stay in the United States. We offer a bespoke mobility service on an international scale, guaranteeing an outstanding passenger experience at all times, anywhere in the world.
Through our network of audited and trusted US partners, we offer the same level of quality in the US as in the countries where Chabé uses its own resources (France, UK, Switzerland and Monaco).
Whether it is a transfer service, roadshow or event we provide the highest quality of service. With extensive experience in delivering international service, we have in depth knowledge of United States and understand what it takes to deliver a consistent high standard of service with the necessary Duty of Care that is paramount.
MORE INFORMATION ABOUT OUR INTERNATIONAL NETWORK
Entry to the US will be permitted in early November subject to the following conditions.
Anyone wishing to travel to the USA must
In addition, airlines will have to collect the contact details of their passengers so that they can be contacted if anyone on the flight is declared positive for COVID.
The list of recognized vaccines allowing travelers to enter the country has not been fully disclosed. However, people immunized with the vaccines identified by the US drug agency, the FDA, i.e. those made by Pfizer-BioNTech, Moderna and Johnson&Johnson, are already authorised to enter the United States from November. According to Thierry Breton, who is in charge of coordinating the European Union’s supply of Covid vaccines, Europeans vaccinated with AstraZeneca’s serum should be able to come to the United States in November, even though the vaccine is not recognised by the US Food and Drug Administration.